stockrowGilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.3%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. (GILD) Gross margin
Gilead Sciences, Inc.'s gross margin over the twelve months to 30 September 2026 was 79.9%, up 1.1 percentage points from fiscal 2025 (78.8%). Over the past ten years it has ranged from 75.8% (fiscal 2021) to 87.7% (fiscal 2015); the current reading is higher than 45% of that period. That is above the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 78.8% | 0.57 |
| FY2024 | 78.3% | 2.22 |
| FY2023 | 76.0% | (3.22) |
| FY2022 | 79.3% | 3.44 |
| FY2021 | 75.8% | (5.66) |
| FY2020 | 81.5% | 2.30 |
| FY2019 | 79.2% | 1.11 |
| FY2018 | 78.1% | (5.19) |
| FY2017 | 83.3% | (2.72) |
| FY2016 | 86.0% | (1.75) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 81.1% | 1.31 |
| Jun 2026 | 79.8% | 0.52 |
| Mar 2026 | 79.2% | (0.27) |
| Dec 2025 | 79.5% | (0.29) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. | 79.9% |
| NVS Novartis AG compare | 74.9% |
| SNY Sanofi compare | 73.4% |
| PFE Pfizer Inc. compare | 73.4% |
| MRK Merck & Co., Inc. compare | 71.8% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement